iQure Pharma is a Princeton, NJ-based biotech focused on developing therapeutics for neuropathic pain, epilepsy, and wider neurodegenerative diseases. The company is advancing preclinical candidates iQ-007 and iQ-008. iQ-007 has demonstrated positive results in NIH ETSP tests suggesting activity against pain, epilepsy, and potentially neurodegenerative conditions. iQ-008, described as a novel analgesic compound, has progressed within the NIH PSPP program for pain and is moving to the next stage of that screening platform under the HEAL initiative. Led by Coo Pawel Zolnierczyk, iQure intends to use the funds raised to support research into neuropathic pain compounds. Financially, iQure completed an early closing of its Series A, raising $600K from Keiretsu Mid-Atlantic and associated business angels.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2022